Alzheimer's Disease/Cognition News

ORLANDO, Fla. — Among a cohort of patients within the Atherosclerosis Risk in Communities study, no link was found between late-life depression and global amyloid deposition, according to a poster at the American Neurological Association.

The FDA has granted 510(k) clearance to a Centiloid scaling apparatus software for positron emission tomography-based amyloid imaging to evaluate individuals for Alzheimer’s disease-related pathology.

Patients with preclinical Alzheimer’s disease had significantly greater putative retinal gliosis compared with controls, according to study results published in Investigative Ophthalmology & Visual Science.

CHICAGO — In this Healio video exclusive, Pauline M. Maki, PhD, provides three takeaways from her talk on cognition and hormone therapy during menopause at the Annual Meeting of The Menopause Society.

Increasing depressive symptoms among cognitively unimpaired older adults appeared significantly associated with early amyloid accumulation in brain regions involved in emotional control, according to a study published in JAMA Network Open.

Type 2 diabetes has emerged as a possible risk factor contributing to the development of dementia, but one class of agents used to treat the disease may provide greater protective effects, study results published in BMJ showed.

The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.

PHILADELPHIA — The creation of microstimulation models may help predict population-level dementia burdens by the year 2050; however, the success of the model is dependent on the size and quality of the data, according to a presenter.

Results of an ongoing clinical trial showed that an oral, small molecule oligomer antagonist used to treat mild to moderate Alzheimer’s disease boosted connectivity between regions of the brain as a promising sign of cognitive improvement.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.